Ardelyx (ARDX) Stock Forecast & Price Target

Ardelyx is viewed positively because tenapanor gives it two differentiated, first-in-class commercial assets in large, underserved markets, with Ibsrela positioned in IBS-C and Xphozah addressing phosphate control in CKD patients on dialysis. Despite the 2Q26 setback from reimbursement headwinds, the company still posted Ibsrela revenue of $86.2M and Xphozah revenue of $31.9M, while management reiterated conviction in $1B Ibsrela revenue and a path to profitability in 2027, supported by a >95% gross margin. The outlook also benefits from operational levers such as a doubled reimbursement manager team, a 144-rep sales force, strong specialty pharmacy execution, $281.8M in cash and equivalents, and the optionality of CIC expansion with Phase 3 enrollment on track to complete by YE26.

Ardelyx is facing a negative fundamental backdrop as Chief Commercial Officer Eric Foster’s planned departure on 8/28/26 raises execution risk at a time when commercial momentum is critical. The company also remains exposed to regulatory uncertainty, since approval paths may require additional or longer studies, and any inability to secure product labels with the right features could limit adoption of IBSRELA and XPHOZAH. In addition, reimbursement pricing changes could pressure revenue realization and undermine traction, leaving the business vulnerable despite its first-in-class pipeline and marketed assets.